Takeda

For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation. Today, our organization spans the globe—colleagues across business units and functions face challenges head-on to deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.

As a values-based, R&D-driven biopharmaceutical leader headquartered in Japan, we focus our R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. In addition to our R&D efforts, we’re laser-focused on harnessing the power of data, digital, and technology to improve health outcomes for patients across the globe.

Since our founding in Japan, integrity and putting patients first have been at the heart of our identity. We’re proud of our employees and their commitment to improving the quality of life for patients, and to working with our partners in health care in approximately 80 countries and regions. With each new breakthrough comes opportunities to develop your career, hone new skills, and create a brighter future.

For more information, visit https://jobs.takeda.com/

650 East Kendall Street Cambridge MA 02421 US
  • Featured Employer Badge
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • Takeda Top Global Employer 2024
  • Takeda LinkedIn Top 2024.png
  • 2025BPTW_GeneralBadge_FullColor.png
  • Takeda Disability Equality 2024
  • Takeda BGH 2024.png
CULTURE

At Takeda, we share a vision for the future where health care is more accessible, inclusive, sustainable, and affordable for all. And we believe our people are our greatest promise for delivering it. Individually, from R&D to IT, Finance to Maintenance, and every department in between, each of us brings the expertise, dedication, passion, and courage it takes to make history every day and change health care forever.

We’re grounded in over 240 years of history and are inspired each and every day by the possibility our future holds. Since our founding in Japan in 1781, integrity and putting patients first have been at the heart of our identity. These principles are ingrained in our culture and inspire our vision for the future. Our founding values remain core to our culture today and will inspire ideas that help you create a better tomorrow.

Across all parts of the business and corners of the world, our values unite and guide us. Our values are more than words on a page. They guide everything we do, uniting our teams across the world and lead us into the future. Our teams span the globe and work across a broad range of therapeutic areas, but we are connected by a shared values system. Bring your collaborative mindset and commitment and help us deliver the vision.

We’re dedicated to patients, our people, and the planet and proud of the contributions made by all our employees to drive impact. Each person’s contributions help us do better for patients, our fellow colleagues, and the planet. Take pride in knowing you help create a brighter future for patients, people, and the planet.

We’re constantly evolving—acting with endurance in our steadfast pursuit to achieve the best outcomes for our patients. We’re future-focused, delivering life-changing treatments through innovation. The drive to do better for patients means we are continuously evolving as a company and within our individual roles. Pursue new possibilities for patients while discovering new opportunities to grow your career.

DIVERSITY, EQUITY & INCLUSION

Across Takeda, we embrace and celebrate diversity, while striving to give patients and our people equitable access to opportunities that help them achieve their full potential. We take a values-based approach to inclusive patient experiences, inclusive work environments, workforce diversity and sustainable societal impact. We believe that diverse perspectives and experiences are key drivers of innovation. This starts with fostering an environment that creates a sense of belonging, allowing not only for everyone to have a voice, but a voice that is heard and valued.

NEWS
It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods.
Takeda Pharmaceutical released data from its Phase IIIb/IV clinical trial for Adynovate. On the same day, jurors in a Delaware federal court ordered Takeda’s Baxalta unit to pay $155.19 million to Bayer AG for infringing a patent for Adynovate.
Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s a theme among them, it seems lower earnings per share are forecast for the year.
Dengue fever affects as many as 400 million people annually and is caused by one of four related viruses transmitted by mosquitoes. The trial showed the vaccine was efficacious in preventing dengue fever by any of the four serotypes.
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.
On Tuesday, Takeda Pharmaceutical finally wrapped up its $62 billion acquisition of Shire plc. As the combined companies continue to merge and shape their combined roles, Chief Executive Officer Christophe Weber is already eying potential deals to offset some of the debt the company garnered.
Last year’s sole mega-deal, the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical is finally closed. Takeda, 237 years old, is now a top 10 international drug company.
This morning, Osaka, Japan-based Takeda struck deals with Memorial Sloan Kettering Cancer Center, Noile-Immune Biotech Inc. and Crescendo Biologics.
Paris-based Sanofi announced it was transferring its listing of American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market starting end-of-day December 31, 2018. They will start trading on January 2, 2019.
JOBS
IN THE PRESS